Postibrutinib outcomes in patients with mantle cell lymphoma

Peter Martin, Kami Maddocks, John P. Leonard, Jia Ruan, Andre Goy, Nina Wagner-Johnston, Simon Rule, Ranjana Advani, David Iberri, Tycel Phillips, Stephen Spurgeon, Eliana Kozin, Katherine Noto, Zhengming Chen, Wojciech Jurczak, Rebecca Auer, Ewa Chmielowska, Stephan Stilgenbauer, Johannes Bloehdorn, Craig PortellMichael E. Williams, Martin Dreyling, Paul M. Barr, Selina Chen-Kiang, Maurizio DiLiberto, Richard R. Furman, Kristie A. Blum

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Despite unprecedented clinical activity inmantle cell lymphoma (MCL), primary and acquired resistance to ibrutinib is common. The outcomes and ideal management of patients who experience ibrutinib failure are unclear. We performed a retrospective cohort study of all patients withMCLwho experienced disease progressionwhile receiving ibrutinib across 15 international sites. Medical records were evaluated for clinical characteristics, pathological and radiological data, and therapies used pre- and postibrutinib. A total of 114 subjects met eligibility criteria. The median number of prior therapies was 3 (range, 0-10). The Mantle Cell Lymphoma International Prognostic Index (MIPI) scores at the start of ibrutinib were low, intermediate, and high in 46%, 31%, and 23% of patients, respectively. Of patients with available data prior to ibrutinib and postibrutinib, 34 of 47 and 11 of 12 had a Ki67 >30%. The median time on ibrutinib was 4.7 months (range 0.7-43.6). The median overall survival (OS) following cessation of ibrutinib was 2.9 months (95% confidence interval [CI], 1.6-4.9). Of the 104 patients with data available, 73 underwent subsequent treatment an average of 0.3 months after stopping ibrutinib with a median OS of 5.8 months (95% CI, 3.7-10.4). Multivariate Cox regression analysis of MIPI before postibrutinib treatment, and subsequent treatment with bendamustine, cytarabine, or lenalidomide failed to reveal any association with OS. Poor clinical outcomes were noted in the majority of patients with primary or secondary ibrutinib resistance. We could not identify treatments that clearly improved outcomes. Future trials should focus on understanding the mechanisms of ibrutinib resistance and on treatment after ibrutinib.

Original languageEnglish (US)
Pages (from-to)1559-1563
Number of pages5
JournalBlood
Volume127
Issue number12
DOIs
StatePublished - Mar 24 2016

Fingerprint

Mantle-Cell Lymphoma
Therapeutics
Survival
PCI 32765
Confidence Intervals
Cytarabine
Regression analysis
Medical Records
Lymphoma
Cohort Studies
Retrospective Studies
Regression Analysis

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., ... Blum, K. A. (2016). Postibrutinib outcomes in patients with mantle cell lymphoma. Blood, 127(12), 1559-1563. https://doi.org/10.1182/blood-2015-10-673145

Postibrutinib outcomes in patients with mantle cell lymphoma. / Martin, Peter; Maddocks, Kami; Leonard, John P.; Ruan, Jia; Goy, Andre; Wagner-Johnston, Nina; Rule, Simon; Advani, Ranjana; Iberri, David; Phillips, Tycel; Spurgeon, Stephen; Kozin, Eliana; Noto, Katherine; Chen, Zhengming; Jurczak, Wojciech; Auer, Rebecca; Chmielowska, Ewa; Stilgenbauer, Stephan; Bloehdorn, Johannes; Portell, Craig; Williams, Michael E.; Dreyling, Martin; Barr, Paul M.; Chen-Kiang, Selina; DiLiberto, Maurizio; Furman, Richard R.; Blum, Kristie A.

In: Blood, Vol. 127, No. 12, 24.03.2016, p. 1559-1563.

Research output: Contribution to journalArticle

Martin, P, Maddocks, K, Leonard, JP, Ruan, J, Goy, A, Wagner-Johnston, N, Rule, S, Advani, R, Iberri, D, Phillips, T, Spurgeon, S, Kozin, E, Noto, K, Chen, Z, Jurczak, W, Auer, R, Chmielowska, E, Stilgenbauer, S, Bloehdorn, J, Portell, C, Williams, ME, Dreyling, M, Barr, PM, Chen-Kiang, S, DiLiberto, M, Furman, RR & Blum, KA 2016, 'Postibrutinib outcomes in patients with mantle cell lymphoma', Blood, vol. 127, no. 12, pp. 1559-1563. https://doi.org/10.1182/blood-2015-10-673145
Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Mar 24;127(12):1559-1563. https://doi.org/10.1182/blood-2015-10-673145
Martin, Peter ; Maddocks, Kami ; Leonard, John P. ; Ruan, Jia ; Goy, Andre ; Wagner-Johnston, Nina ; Rule, Simon ; Advani, Ranjana ; Iberri, David ; Phillips, Tycel ; Spurgeon, Stephen ; Kozin, Eliana ; Noto, Katherine ; Chen, Zhengming ; Jurczak, Wojciech ; Auer, Rebecca ; Chmielowska, Ewa ; Stilgenbauer, Stephan ; Bloehdorn, Johannes ; Portell, Craig ; Williams, Michael E. ; Dreyling, Martin ; Barr, Paul M. ; Chen-Kiang, Selina ; DiLiberto, Maurizio ; Furman, Richard R. ; Blum, Kristie A. / Postibrutinib outcomes in patients with mantle cell lymphoma. In: Blood. 2016 ; Vol. 127, No. 12. pp. 1559-1563.
@article{cd298bedd578439b8fa9b28ded473b34,
title = "Postibrutinib outcomes in patients with mantle cell lymphoma",
abstract = "Despite unprecedented clinical activity inmantle cell lymphoma (MCL), primary and acquired resistance to ibrutinib is common. The outcomes and ideal management of patients who experience ibrutinib failure are unclear. We performed a retrospective cohort study of all patients withMCLwho experienced disease progressionwhile receiving ibrutinib across 15 international sites. Medical records were evaluated for clinical characteristics, pathological and radiological data, and therapies used pre- and postibrutinib. A total of 114 subjects met eligibility criteria. The median number of prior therapies was 3 (range, 0-10). The Mantle Cell Lymphoma International Prognostic Index (MIPI) scores at the start of ibrutinib were low, intermediate, and high in 46{\%}, 31{\%}, and 23{\%} of patients, respectively. Of patients with available data prior to ibrutinib and postibrutinib, 34 of 47 and 11 of 12 had a Ki67 >30{\%}. The median time on ibrutinib was 4.7 months (range 0.7-43.6). The median overall survival (OS) following cessation of ibrutinib was 2.9 months (95{\%} confidence interval [CI], 1.6-4.9). Of the 104 patients with data available, 73 underwent subsequent treatment an average of 0.3 months after stopping ibrutinib with a median OS of 5.8 months (95{\%} CI, 3.7-10.4). Multivariate Cox regression analysis of MIPI before postibrutinib treatment, and subsequent treatment with bendamustine, cytarabine, or lenalidomide failed to reveal any association with OS. Poor clinical outcomes were noted in the majority of patients with primary or secondary ibrutinib resistance. We could not identify treatments that clearly improved outcomes. Future trials should focus on understanding the mechanisms of ibrutinib resistance and on treatment after ibrutinib.",
author = "Peter Martin and Kami Maddocks and Leonard, {John P.} and Jia Ruan and Andre Goy and Nina Wagner-Johnston and Simon Rule and Ranjana Advani and David Iberri and Tycel Phillips and Stephen Spurgeon and Eliana Kozin and Katherine Noto and Zhengming Chen and Wojciech Jurczak and Rebecca Auer and Ewa Chmielowska and Stephan Stilgenbauer and Johannes Bloehdorn and Craig Portell and Williams, {Michael E.} and Martin Dreyling and Barr, {Paul M.} and Selina Chen-Kiang and Maurizio DiLiberto and Furman, {Richard R.} and Blum, {Kristie A.}",
year = "2016",
month = "3",
day = "24",
doi = "10.1182/blood-2015-10-673145",
language = "English (US)",
volume = "127",
pages = "1559--1563",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Postibrutinib outcomes in patients with mantle cell lymphoma

AU - Martin, Peter

AU - Maddocks, Kami

AU - Leonard, John P.

AU - Ruan, Jia

AU - Goy, Andre

AU - Wagner-Johnston, Nina

AU - Rule, Simon

AU - Advani, Ranjana

AU - Iberri, David

AU - Phillips, Tycel

AU - Spurgeon, Stephen

AU - Kozin, Eliana

AU - Noto, Katherine

AU - Chen, Zhengming

AU - Jurczak, Wojciech

AU - Auer, Rebecca

AU - Chmielowska, Ewa

AU - Stilgenbauer, Stephan

AU - Bloehdorn, Johannes

AU - Portell, Craig

AU - Williams, Michael E.

AU - Dreyling, Martin

AU - Barr, Paul M.

AU - Chen-Kiang, Selina

AU - DiLiberto, Maurizio

AU - Furman, Richard R.

AU - Blum, Kristie A.

PY - 2016/3/24

Y1 - 2016/3/24

N2 - Despite unprecedented clinical activity inmantle cell lymphoma (MCL), primary and acquired resistance to ibrutinib is common. The outcomes and ideal management of patients who experience ibrutinib failure are unclear. We performed a retrospective cohort study of all patients withMCLwho experienced disease progressionwhile receiving ibrutinib across 15 international sites. Medical records were evaluated for clinical characteristics, pathological and radiological data, and therapies used pre- and postibrutinib. A total of 114 subjects met eligibility criteria. The median number of prior therapies was 3 (range, 0-10). The Mantle Cell Lymphoma International Prognostic Index (MIPI) scores at the start of ibrutinib were low, intermediate, and high in 46%, 31%, and 23% of patients, respectively. Of patients with available data prior to ibrutinib and postibrutinib, 34 of 47 and 11 of 12 had a Ki67 >30%. The median time on ibrutinib was 4.7 months (range 0.7-43.6). The median overall survival (OS) following cessation of ibrutinib was 2.9 months (95% confidence interval [CI], 1.6-4.9). Of the 104 patients with data available, 73 underwent subsequent treatment an average of 0.3 months after stopping ibrutinib with a median OS of 5.8 months (95% CI, 3.7-10.4). Multivariate Cox regression analysis of MIPI before postibrutinib treatment, and subsequent treatment with bendamustine, cytarabine, or lenalidomide failed to reveal any association with OS. Poor clinical outcomes were noted in the majority of patients with primary or secondary ibrutinib resistance. We could not identify treatments that clearly improved outcomes. Future trials should focus on understanding the mechanisms of ibrutinib resistance and on treatment after ibrutinib.

AB - Despite unprecedented clinical activity inmantle cell lymphoma (MCL), primary and acquired resistance to ibrutinib is common. The outcomes and ideal management of patients who experience ibrutinib failure are unclear. We performed a retrospective cohort study of all patients withMCLwho experienced disease progressionwhile receiving ibrutinib across 15 international sites. Medical records were evaluated for clinical characteristics, pathological and radiological data, and therapies used pre- and postibrutinib. A total of 114 subjects met eligibility criteria. The median number of prior therapies was 3 (range, 0-10). The Mantle Cell Lymphoma International Prognostic Index (MIPI) scores at the start of ibrutinib were low, intermediate, and high in 46%, 31%, and 23% of patients, respectively. Of patients with available data prior to ibrutinib and postibrutinib, 34 of 47 and 11 of 12 had a Ki67 >30%. The median time on ibrutinib was 4.7 months (range 0.7-43.6). The median overall survival (OS) following cessation of ibrutinib was 2.9 months (95% confidence interval [CI], 1.6-4.9). Of the 104 patients with data available, 73 underwent subsequent treatment an average of 0.3 months after stopping ibrutinib with a median OS of 5.8 months (95% CI, 3.7-10.4). Multivariate Cox regression analysis of MIPI before postibrutinib treatment, and subsequent treatment with bendamustine, cytarabine, or lenalidomide failed to reveal any association with OS. Poor clinical outcomes were noted in the majority of patients with primary or secondary ibrutinib resistance. We could not identify treatments that clearly improved outcomes. Future trials should focus on understanding the mechanisms of ibrutinib resistance and on treatment after ibrutinib.

UR - http://www.scopus.com/inward/record.url?scp=84962325088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962325088&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-10-673145

DO - 10.1182/blood-2015-10-673145

M3 - Article

C2 - 26764355

AN - SCOPUS:84962325088

VL - 127

SP - 1559

EP - 1563

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -